eligibility_summary
Adults ≥18 with T‑cell NHL (protocol‑listed subtypes), ECOG 0–2, measurable PTCL lesion, ≤1 prior CHOP/CHOEP/EPOCH cycle allowed, adequate organ/marrow, contraception, CD4 ≥200 if prior anti‑CD4/alemtuzumab. Exclude: recent therapy/radiation/surgery/immunosuppressants, pregnancy/live vaccine/investigational use, active infection, myocarditis/NYHA III–IV, unstable CNS mets, recent other cancer, hypersensitivity, HIV/HBV/HCV, active TB, allo‑SCT ≤2y/GVHD, active autoimmune disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial adding mogamulizumab to DA‑EPOCH for aggressive T‑cell lymphomas (e.g., PTCL, AITL, ALCL, transformed MF/SS, ATLL). Interventions/mechanisms: Mogamulizumab (Poteligeo) is a defucosylated humanized anti‑CCR4 monoclonal antibody (immunotherapy) that binds CCR4 on malignant T cells (and Tregs), blocks CCR4 chemokine signaling/trafficking, and enhances Fc‑mediated ADCC to deplete CCR4+ cells. DA‑EPOCH is cytotoxic chemotherapy: etoposide (topoisomerase II inhibitor), doxorubicin (anthracycline/topo II, ROS), cyclophosphamide (alkylator), vincristine (vinca microtubule inhibitor), prednisone (glucocorticoid, lympholytic). Targets/pathways: CCR4+ T‑cell clones and chemokine‑driven migration, DNA replication/repair, crosslinking and strand breaks, mitotic spindle, glucocorticoid‑induced apoptosis.